ABB and AMLI Collaborate to Further Advance the Practice of Medical Laboratory Immunology
St. Louis, MO – The American Board of Bioanalysis (ABB) and the Association of Medical Laboratory Immunologists (AMLI) are announcing a collaboration to further advance the practice of medical laboratory immunology.
ABB offers board certification examinations for individuals wishing to pursue a career directing high complexity clinical laboratory testing. As part of the collaboration, AMLI will offer its expertise in medical laboratory immunology and work jointly with ABB to update and revise ABB’s immunology examination for certification of high complexity clinical laboratory directors (HCLDs).
ABB will accept two years of the American Society for Microbiology’s (ASM’s) Committee on Postgraduate Educational Programs (CPEP) training to count toward ABB’s four-year experience requirement for eligibility to sit for the HCLD certification examination. ABB will also waive the requirement to sit for the immunology component of the HCLD certification examination for current diplomates of the American Board of Medical Laboratory Immunology (ABMLI).
“We are very pleased to be able to work with the Association of Medical Laboratory Immunologists. The expertise and knowledge of their members will be invaluable to ABB and its immunology certification and examination program,” says ABB Chairman Brooks A. Keel, Ph.D., HCLD(ABB).
“The AMLI is excited to partner with ABB and support trainees in medical laboratory immunology who are interested in pursuing a career in laboratory medicine. We greatly appreciate the ABB’s expertise and experience in the certification process of clinical laboratory directors and will look forward to a fruitful partnership,” says AMLI President Vijaya Knight, MD, Ph.D., (D)ABMLI.
View original release here (PDF).